{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:53:48Z","timestamp":1791176028520,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.antiviral.2009.10.021","type":"journal-article","created":{"date-parts":[[2009,11,3]],"date-time":"2009-11-03T10:27:32Z","timestamp":1257244052000},"page":"303-315","source":"Crossref","is-referenced-by-count":154,"title":["Viral hepatitis and HIV co-infection"],"prefix":"10.1016","volume":"85","author":[{"given":"Vincent","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Vispo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Labarga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2009.10.021_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J. Hepatol."},{"issue":"5 Suppl.","key":"10.1016\/j.antiviral.2009.10.021_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/hep.22899","article-title":"Monitoring during and after antiviral therapy for hepatitis B","volume":"49","author":"Andersson","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.qai.0000174649.51084.46","article-title":"Risk factors for symptomatic mitochondrial toxicity in HIV\/hepatitis C virus-co-infected patients during interferon plus ribavirin-based therapy","volume":"40","author":"Bani-Sadr","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.021_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAI.0b013e318040b2b6","article-title":"Early virologic failure in HIV-co-infected hepatitis C patients treated with pegIFN\u2013RBV combination: does abacavir play a role?","volume":"45","author":"Bani-Sadr","year":"2007","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.021_bib5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/135965350601100706","article-title":"Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV\/HIV-co-infected patients","volume":"11","author":"Barreiro","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.021_bib6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in HIV and hepatitis C virus co-infected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jhep.2005.11.019","article-title":"Treatment algorithm for chronic hepatitis B in HIV-infected patients","volume":"44","author":"Benhamou","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.10.021_bib8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","article-title":"Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa 2a plus ribavirin","volume":"130","author":"Berg","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib9","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1097\/00002030-200410210-00008","article-title":"Survival in patients with HIV infection and viral hepatitis B or C: a cohort study","volume":"18","author":"Bonacini","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib10","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/jhep.2003.50107","article-title":"Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases","volume":"37","author":"Buti","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib11","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2009.10.021_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2009.10.021_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-2004-828678","article-title":"Treatment with interferons (including pegylated interferons) in patients with chronic hepatitis B","volume":"24","author":"Cooksley","year":"2004","journal-title":"Semin. Liver. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAD.0b013e328012b5ba","article-title":"Utility of week 4 viral response to tailor treatment duration in hepatitis C virus genotype 3\/HIV-co-infected patients","volume":"21","author":"Crespo","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/QAD.0b013e3281053a0c","article-title":"Recent epidemic of acute hepatitis C in HIV-positive men who have sex with men linked to high-risk sexual behaviours","volume":"21","author":"Danta","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/01.qai.0000194238.15831.c7","article-title":"Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV\/hepatitis C virus-co-infected patients","volume":"41","author":"De Ledinghen","year":"2006","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.021_bib17","unstructured":"DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. February 2, 2009 (www.aidsinfo.nih.gov)."},{"key":"10.1016\/j.antiviral.2009.10.021_bib18","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/gast.2002.37061","article-title":"Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B","volume":"123","author":"Di Martino","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib19","series-title":"13th Conference on Retroviruses and Opportunistic Infections","article-title":"February 5\u20138, Sustained virological response in HIV\/HCV co-infected patients with HCV genotype 1 infection who have a rapid virological response at week 4 of treatment with peginterferon alfa-2a plus ribavirin: APRICOT trial","author":"Dieterich","year":"2006"},{"key":"10.1016\/j.antiviral.2009.10.021_bib20","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"issue":"Suppl 2","key":"10.1016\/j.antiviral.2009.10.021_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0168-8278(06)80009-7","article-title":"24 week treatment regimen with peginterferon alpha-2a plus ribavirin in HCV genotype 1 or 4 \u201csuper-responders\u201d","volume":"44","author":"Ferenci","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.10.021_bib22","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM200210173471623","article-title":"Weight loss in HIV-infected patients","volume":"347","author":"Garcia-Benayas","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.021_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.10.021_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2009.10.021_bib25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: Summary of a clinical research workshop","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B virus viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","article-title":"Risk and predictors of mortality associated with chronic hepatitis B infection","volume":"5","author":"Iloeje","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2009.10.021_bib28","first-page":"1003","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update","volume":"24","author":"Keeffe","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2009.10.021_bib29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1097\/01.aids.0000163936.99401.fe","article-title":"Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort","volume":"19","author":"Konopnicki","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib30","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-na\u00efve patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib31","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/520092","article-title":"Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients","volume":"196","author":"Labarga","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib32","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.166.1.49","article-title":"A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B","volume":"166","author":"Lim","year":"2006","journal-title":"Arch. Inter. Med."},{"key":"10.1016\/j.antiviral.2009.10.021_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.20563","article-title":"High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C","volume":"41","author":"Lindahl","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B, AASLD Practice Guidelines","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib37","first-page":"245","article-title":"Acute hepatitis C in HIV-positive individuals","volume":"10","author":"Low","year":"2008","journal-title":"AIDS Rev."},{"key":"10.1016\/j.antiviral.2009.10.021_bib38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1089\/aid.2006.0085","article-title":"Liver fibrosis stage and HCV genotype distribution in HIV\u2013HCV co-infected patients with persistently normal transaminases","volume":"23","author":"Maida","year":"2007","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2009.10.021_bib39","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3","volume":"352","author":"Mangia","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 2","key":"10.1016\/j.antiviral.2009.10.021_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0168-8278(06)80012-7","article-title":"Efficacy of standard dose and fixed dose induction peginterferon alpha-2a plus ribavirin among pegylated interferon alpha-2b\/ribavirin non-responders: interim analysis of the REPEAT study","volume":"44","author":"Marcellin","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.10.021_bib41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/380130","article-title":"Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C\u2014a European collaborative study","volume":"38","author":"Martin-Carbonero","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2893.2006.00839.x","article-title":"Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis","volume":"14","author":"Mart\u00edn-Carbonero","year":"2007","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2009.10.021_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAD.0b013e3282f1da99","article-title":"Undetectable HCV RNA at Hjek 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C","volume":"22","author":"Martin-Carbonero","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2893.2000.00195.x","article-title":"Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections","volume":"7","author":"Mathurin","year":"2000","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2009.10.021_bib45","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.aids.0000218550.85081.59","article-title":"Characteristics of drug resistant HBV in an international collaborative study of HIV\u2013HBV-infected individuals on extended lamivudine therapy","volume":"20","author":"Matthews","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib46","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\/HCV co-infection and liver cirrhosis during interferon-based therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib47","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir\u2014effects on HIV-1 replication and resistance","volume":"356","author":"McMahon","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.021_bib48","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/hep.23208","article-title":"Hepatitis C drug development at a cross-roads","volume":"50","author":"Nelson","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib50","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00126334-200108150-00002","article-title":"Risk factors for severe hepatic injury following the introduction of HAART","volume":"27","author":"N\u00fa\u00f1ez","year":"2001","journal-title":"J. Acquir. Immun. Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.021_bib51","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1097\/00002030-200211220-00023","article-title":"Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine","volume":"16","author":"N\u00fa\u00f1ez","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib52","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1473-3099(05)70141-9","article-title":"Management of patients co-infected with hepatitis B virus and HIV","volume":"5","author":"Nu\u00f1ez","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib53","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/135965350501000512","article-title":"Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C","volume":"10","author":"Nu\u00f1ez","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.021_bib54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1310\/R7B4-Q37L-FAQ7-LQB7","article-title":"Hepatitis C viremia in HIV\/HCV-co-infected patients: lower levels in presence of chronic hepatitis B","volume":"6","author":"N\u00fa\u00f1ez","year":"2005","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.antiviral.2009.10.021_bib55","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in the treatment of chronic hepatitis C in HIV-infected patients: the PRESCO trial","volume":"23","author":"Nu\u00f1ez","year":"2007","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2009.10.021_bib56","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/hep.21388","article-title":"Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127","volume":"44","author":"Peters","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib57","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200411190-00009","article-title":"Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome","volume":"18","author":"Puoti","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/QAI.0b013e3180314b46","article-title":"Hepatitis B virus genotypes and lamivudine resistance mutations in HIV\/hepatitis B virus-co-infected patients","volume":"44","author":"Ramos","year":"2007","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.021_bib59","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2893.2006.00806.x","article-title":"Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV\/HIV-co-infected patients","volume":"14","author":"Ramos","year":"2007","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2009.10.021_bib60","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.qai.0000170034.90438.68","article-title":"Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV\/hepatitis C virus-co-infected patients","volume":"39","author":"Rendon","year":"2005","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.021_bib61","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2007.00535.x","article-title":"EACS guidelines for the clinical management and treatment of chronic hepatitis B and C co-infection in HIV-infected adults","volume":"9","author":"Rockstroh","year":"2008","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2009.10.021_bib62","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-Gomez","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib63","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s15010-004-3080-6","article-title":"Influence of chronic co-infection with hepatitis B and C virus on liver histology","volume":"32","author":"Sagnelli","year":"2004","journal-title":"Infection"},{"key":"10.1016\/j.antiviral.2009.10.021_bib64","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Sakai","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.antiviral.2009.10.021_bib65","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1310\/FRWE-HCGF-K3BG-DG8P","article-title":"Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C including patients on interferon plus ribavirin","volume":"6","author":"Sanchez-Conde","year":"2005","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.antiviral.2009.10.021_bib66","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1086\/506440","article-title":"Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase","volume":"43","author":"Sanchez-Conde","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2006.05.016","article-title":"Peginterferon alfa-2a plus ribavirin for 72 weeks in chronic hepatitis C patients without a response by week 4","volume":"131","author":"S\u00e1nchez-Tapias","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3748\/wjg.v13.i1.14","article-title":"Hepatitis B virus taxonomy and hepatitis B virus genotypes","volume":"13","author":"Schaefer","year":"2007","journal-title":"W. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2009.10.021_bib69","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1097\/01.aids.0000189563.79976.05","article-title":"Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir","volume":"19","author":"Sheldon","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib70","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerase mutations in HIV co-infected patients treated with tenofovir","volume":"10","author":"Sheldon","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.021_bib71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/QAI.0b013e318154bd89","article-title":"Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV\/HIV-co-infected patients failing antiretroviral therapies with anti-HBV activity","volume":"46","author":"Sheldon","year":"2007","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.021_bib72","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jac\/dkn014","article-title":"Hepatitis B virus escape mutants induced by antiviral therapy","volume":"61","author":"Sheldon","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2009.10.021_bib73","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/135965350801300110","article-title":"Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV\u2013HBV\u2013HDV-co-infected patients?","volume":"13","author":"Sheldon","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.021_bib74","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2004.11.059","article-title":"Viral kinetics in hepatitis C or hepatitis C\/HIV-infected patients","volume":"128","author":"Sherman","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib75","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/clinids\/23.3.585","article-title":"Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV","volume":"23","author":"Soriano","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib76","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00002030-200303280-00015","article-title":"Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis?","volume":"17","author":"Soriano","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib77","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/135965350400900411","article-title":"Hepatitis C virus-RNA clearance in HIV-co-infected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin","volume":"9","author":"Soriano","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.021_bib78","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/135965350400900616","article-title":"Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies","volume":"9","author":"Soriano","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.021_bib79","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/088922204323048096","article-title":"Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients","volume":"20","author":"Soriano","year":"2004","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2009.10.021_bib80","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1097\/01.aids.0000247583.38943.95","article-title":"Regression of liver fibrosis in hepatitis C virus\/HIV-co-infected patients alter treatment with pegylated interferon plus ribavirin","volume":"20","author":"Soriano","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib81","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients co-infected with HIV and HCV: 2007 Updated recommendations from the HCV\u2013HIV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.021_bib82","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1086\/512679","article-title":"Treatment of chronic hepatitis B and\/or C in HIV-infected patients with multiple viral hepatitis infections","volume":"195","author":"Soriano","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib83","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/QAD.0b013e3282f8b46f","article-title":"Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-HBV International Panel","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS."},{"key":"10.1016\/j.antiviral.2009.10.021_bib84","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/595848","article-title":"New therapies for hepatitis C virus infection","volume":"48","author":"Soriano","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib85","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1086\/598611","article-title":"Spontaneous viral clearance, viral load, and genotype distribution of HCV in European HIV-infected patients with anti-HCV antibodies (reply)","volume":"199","author":"Soriano","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib86","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2009.10.021_bib87","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.antiviral.2009.10.021_bib88","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome wide association of IL28B with response to pegylated interferon alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.antiviral.2009.10.021_bib89","doi-asserted-by":"crossref","first-page":"34218","DOI":"10.1074\/jbc.M806797200","article-title":"Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase","volume":"283","author":"Tchesnokov","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2009.10.021_bib90","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.021_bib91","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.10.021_bib92","first-page":"40","article-title":"Treatment of HIV-HBV co-infection: clinical and virological issues","volume":"9","author":"Thio","year":"2007","journal-title":"AIDS Rev."},{"key":"10.1016\/j.antiviral.2009.10.021_bib93","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: host, viral and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2009.10.021_bib94","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.10.021_bib95","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3748\/wjg.v13.i1.125","article-title":"Antiviral therapy and resistance with hepatitis B virus infection","volume":"13","author":"Tillmann","year":"2007","journal-title":"W. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2009.10.021_bib96","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/379255","article-title":"HCV and HIV dynamics during HCV treatment in HCV\/HIV co-infection","volume":"188","author":"Torriani","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib97","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.021_bib98","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2893.2007.00860.x","article-title":"Safety and efficacy of an induction-dose of pegylated alpha-2a on early hepatitis C virus kinetics in HIV\/HCV co-infected patients: the CORAL-1 multicentre pilot study","volume":"14","author":"Tural","year":"2007","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2009.10.021_bib99","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1086\/518796","article-title":"Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission","volume":"196","author":"van de Laar","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.021_bib100","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/135965350801300303","article-title":"Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir","volume":"13","author":"Vispo","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.021_bib101","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.gastro.2005.05.008","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3 chronic hepatitis C","volume":"129","author":"von Wagner","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2009.10.021_bib102","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2005.10.003","article-title":"Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia","volume":"44","author":"Zeuzem","year":"2006","journal-title":"J. Hepatol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354209005087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354209005087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T12:13:16Z","timestamp":1710677596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354209005087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0166354209005087"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2009.10.021","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}